

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3367660

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
GLAXOSMITHKLINE	01/10/2011
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	EXELIXIS, INC.
<b>Street Address:</b>	210 EAST GRAND AVENUE
<b>City:</b>	SOUTH SAN FRANCISCO
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	94080
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Patent Number:</b>	8673912
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(269)337-7711
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	269-337-7710
<b>Email:</b>	patents@honigman.com
<b>Correspondent Name:</b>	HONIGMAN MILLER SCHWARTZ AND COHN LLP
<b>Address Line 1:</b>	350 EAST MICHIGAN AVENUE
<b>Address Line 2:</b>	SUITE 300
<b>Address Line 4:</b>	KALAMAZOO, MICHIGAN 49007
<b>NAME OF SUBMITTER:</b>	AMY PETERS
<b>SIGNATURE:</b>	/Amy Peters/
<b>DATE SIGNED:</b>	05/26/2015
<b>Total Attachments: 2</b>	
source=EX09-007 Assignment - GSK to EXELIXIS#page1.tif	
source=EX09-007 Assignment - GSK to EXELIXIS#page2.tif	

## ASSIGNMENT

WHEREAS I/we, GlaxoSmithKline, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939, have previously entered into an agreement with Exelixis, Inc., South San Francisco, CA, to assign all of our right, title and interest in and to any and all inventions made or conceived or reduced to practice during the course of our employment with Exelixis, and further agreed to execute additional assignment documents to assist Exelixis with respect to its proprietary rights, and wherein we, during the course of our employment with Exelixis have invented **Crystalline Forms of N-[3-fluoro-4-((6-(methoxy)-7-[(3-morpholin-4-yl)propyl]oxy]-quinolin-4-yl)oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide** (hereinafter "Invention"), disclosed in an application for United States patent, said application filed on July 17, 2009, serial no. 61/226,509.

Whereas Exelixis, Inc., 249 East Grand Avenue, P.O. Box 511, South San Francisco, California 94083-0511 (hereinafter referred to as Assignee) is desirous of obtaining an assignment document that indicates that it has received all the right, title and interest to said Invention.

Now, therefore, and in consideration of good and valuable consideration, the receipt and sufficiency whereof are hereby acknowledged, we have assigned to said Assignee and said Assignee's legal representatives, successors and assigns, the entire right, title, and interest (a) in and to said application and said Invention; (b) in and to all rights to apply for foreign patents on said invention; (c) in and to any and all applications filed and any and all patents granted on said Invention in the United States or any foreign country, including each and every application filed and each and every patent granted on any application which is a divisional, substitution, continuation or nonprovisional 37 CFR 1.53(b) application of any of said applications; and (d) in and to each and every reissue or extensions of any of said patents; and we do hereby authorize and request the Commissioner of Patents and Trademarks to issue said Letters Patent to the above-mentioned Assignee agreeably with the terms of this agreement.

We hereby authorize the above-mentioned Assignee or its legal representative to insert in this instrument the filing date and serial number of said application or any other information that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

We have conveyed to said Assignee the entire right to make application on its own behalf for protection of said Invention in countries foreign to the United States and where expedient to claim under the International Convention or other international arrangement for any such application the date of the said United States application (or other application if any there be) in priority to other applications; and we have agreed that we will at any time upon request, without further or additional compensation or additional consideration, but at the expense of the said Assignee, execute such additional assignments and other writings and do such additional acts as said Assignee may deem necessary or desirable or perfect the Assignee's enjoyment of this grant, and render all

